The IGF1-R has a well established role in tumorigenesis, however the recent failure of the IGF1-R monoclonal antibody figitumumab in NSCLC trials has questioned whether targeting this pathway alone will lead to a therapeutic benefit. The gene discussed is IGF1R; the disease is non-small cell lung carcinoma.